Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors

Sodium–glucose cotransport 2 inhibitors (SGLT2i) lower plasma glucose but stimulate endogenous glucose production (EGP). The current study examined the effect of dapagliflozin on EGP while clamping plasma glucose, insulin, and glucagon concentrations at their fasting level. Thirty-eight patients wit...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetes
Auteurs principaux: Alatrach, Mariam, Laichuthai, Nitchakarn, Martinez, Robert, Agyin, Christina, Ali, Ali Muhammed, Al-Jobori, Hussein, Lavynenko, Olga, Adams, John, Triplitt, Curtis, DeFronzo, Ralph, Cersosimo, Eugenio, Abdul-Ghani, Muhammad
Format: Artigo
Langue:Inglês
Publié: American Diabetes Association 2020
Sujets:
Pathophysiology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7085246/
https://ncbi.nlm.nih.gov/pubmed/31915153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db19-0770
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires